Miguel Ángel TempranoEconomía, geopolítica e inversión
ES·EN

Forty years of analysing the markets and the geopolitics that drive them.

Investment fund manager, director and financial analyst. Recognised as one of Spain’s top 100 financiers of the year by Actualidad Económica magazine. University lecturer and regular contributor to radio, television and the financial press.

Miguel Ángel Temprano
The question is not whether Wuhan had a BSL-4 facility, but which viruses were being manipulated, where and under what conditions.
Column No. 52, entitled ‘Wuhan: the origin that, six years on, we still cannot explain’
40+

years of professional experience

23

years managing investment funds

16

countries in which he has set up companies

52

columns published since 2019

About me

PhD candidate in economics, awaiting defence of my thesis. In my research, I analyse the current validity of the quantitative theory of money, formulated by Nobel laureate Milton Friedman. I propose an update of this theory to reflect today’s economy, which is characterised by levels of globalisation and digitalisation very different from those of the 1960s. I demonstrate the validity of this reformulation using advanced econometric methods. I hold an MBA from IE Business School. In addition to my university studies in economics, I hold a degree in Biochemistry and Fundamental Biology.

A 63-year-old Spanish economist, born in Madrid, with over forty years’ experience in the management of multinational companies and in the management of investment funds, in both private equity and public equity.

I spent the first twenty years of my professional career in the ‘real’ economy – the sector that manufactures goods and provides services other than financial ones. The Americans call it ‘Main Street’. I worked in telecommunications technology at Wandel & Goltermann; in logistics at Mayne Nickless in London; and at EXPAL, a leading company in the fashion and defence sectors. From there, I made the leap into the financial world, where I have spent 25 years managing investment funds comprising both listed and unlisted securities. I have headed two fund management companies.
Over these 40 years, I have had to negotiate and deal with all sorts of counterparties. From executives at large multinationals to all manner of politicians, which has shown me that it is not enough simply to understand one’s own business; one must also understand why others make the decisions they do, decisions that are often shaped by geopolitics. 

He has set up companies in sixteen countries across four continents and forged strategic alliances in twenty-four. He has served on boards of directors in Spain, Europe, Latin America, Africa and Asia, and has lectured on business valuation and strategy.

The column

View all 51 columns
7 de septiembre de 2026 · Salud

El RNAm vuelve al cáncer, una tecnología que tardó sesenta años en llegar hasta aquí

Durante la pandemia mucha gente creyó que la tecnología del RNA mensajero acababa de inventarse para fabricar vacunas contra la COVID. En realidad,su tecnología de fabricación in vitro llevaba décadas abriéndose camino y ya se había probado contra el cáncer.

Aquí se enumera una muestra de las intervenciones en medios. Si quieres ver todas, o alguna en particular, las tienes disponibles en el Archivo de intervenciones.

DateMediaProgramme or headline
3 June 2025Business TVGold SummitWatch video
21 Aug 2024Intereconomía RadioMarket close: What to expect from Jackson Hole and the Federal Reserve’s rate cutsListen
15 March 2024Business TVNATO, Macron and Ukraine: Interview with Eva VillanuevaWatch video
16 Dec 2023Trece TVThe Big QuestionWatch video
6 July 2023Radio IntereconomíaGlobal outlook: Interest rate rises and their limited impact on core inflationListen
31 May 2022CitywireEverything suggests we may be heading for a recession in 2023Read
23 Aug 2020El PaísSICAVs are cursed products in SpainRead

There are no such entries in this selection.

Analysis and technical notes

All documents

Recibe cada columna en tu correo

Se te informará cada vez que se publique un nuevo contenido: columna, análisis o nota técnica. Sin publicidad y sin ceder tus datos a nadie.

Puedes darte de baja con un clic en cualquier envío.